Elixir Associates reposted this
Great news in the world of medicine - the FDA has approved selpercatinib for use in pediatric patients battling thyroid cancer. As of June 12, selpercatinib extends a lifeline to adults and children older than 2 years with certain advanced thyroid cancers. This milestone represents more than just another treatment option; clinical evidence is compelling, with a significant portion of patients showing favorable responses. While we should be mindful of the side effects, the potential benefits for individuals with RET fusion-positive thyroid cancer are too substantial to overlook. #HealthcareAdvancement #FDAApproval #MedicalInnovation
